Citadel Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-48,200
| Closed | -$1.91M | – | 13810 |
|
|
2026
Q1 | $1.91M | Buy |
48,200
+10,800
| +29% | +$276K | ﹤0.01% | 6145 |
|
|
2025
Q4 | $935K | Sell |
37,400
-57,600
| -61% | -$1.46M | ﹤0.01% | 7546 |
|
|
2025
Q3 | $2.3M | Buy |
95,000
+55,000
| +138% | +$978K | ﹤0.01% | 5784 |
|
|
2025
Q2 | $526K | Buy |
40,000
+22,800
| +133% | +$289K | ﹤0.01% | 8513 |
|
|
2025
Q1 | $247K | Buy |
17,200
+16,800
| +4,200% | +$275K | ﹤0.01% | 10013 |
|
|
2024
Q4 | $6.7K | Sell |
400
-29,100
| -99% | -$482K | ﹤0.01% | 13780 |
|
|
2024
Q3 | $472K | Buy |
29,500
+26,500
| +883% | +$325K | ﹤0.01% | 8387 |
|
|
2024
Q2 | $27.1K | Sell |
3,000
-2,000
| -40% | -$19K | ﹤0.01% | 12365 |
|
|
2024
Q1 | $56.5K | Buy |
5,000
+1,000
| +25% | +$9.47K | ﹤0.01% | 12056 |
|
|
2023
Q4 | $31.8K | Buy |
4,000
+1,900
| +90% | +$12.7K | ﹤0.01% | 12218 |
|
|
2023
Q3 | $13.6K | Sell |
2,100
-3,200
| -60% | -$21.9K | ﹤0.01% | 12914 |
|
|
2023
Q2 | $32.8K | Buy |
+5,300
| New | +$25.1K | ﹤0.01% | 12266 |
|
|
2023
Q1 | – | Sell |
-1,000
| Closed | -$3.1K | – | 14807 |
|
|
2022
Q4 | $3.1K | Buy |
+1,000
| New | +$3.71K | ﹤0.01% | 14250 |
|
Citadel Advisors's CNTA Position: Q2 2026 in Review
Citadel Advisors sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 598,197 shares — an estimated $23.8M sold.
Citadel Advisors first reported a position in CNTA in Q2 2021 and held it in 18 quarters. The position peaked at $23.8M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- Citadel Advisors reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Citadel Advisors sold 598,197 Centessa Pharmaceuticals shares in Q2 2026, an estimated $23.8M.
- Citadel Advisors first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 18 quarters.
- Citadel Advisors's Centessa Pharmaceuticals position peaked at $23.8M in Q1 2026.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.